Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: A Canadian consensus

Stephen Couban, L. Savoie, Y. A. Abou Mourad, B. Leber, M. Minden, R. Turner, V. Palada, N. Shehata, A. Christofides, S. Lachance

Résultat de recherche: Articleexamen par les pairs

14 Citations (Scopus)

Résumé

Adult Philadelphia chromosome-positive (Ph+) or BCR-ABL-positive (BCR-ABL+) acute lymphoblastic leukemia (all) is an acute leukemia previously associated with a high relapse rate, short diseasefree survival, and poor overall survival. In adults, allogeneic hematopoietic cell transplant in first remission remains the only proven curative strategy for transplant-eligible patients. The introduction of tyrosine kinase inhibitors (TKIS) in the treatment of patients with Ph+ or BCR-ABL+ ALL has significantly improved the depth and duration of complete remission, allowing more patients to proceed to transplantation. Although tkis are now considered a standard of care in this setting, few randomized trials have examined the optimal use of TKIS in patients with Ph+ ALL. Questions of major importance remain, including the best way to administer these medications, the choice of tki to administer, and the schedule and the duration to use. We present the results of a systematic review of the literature with consensus recommendations based on the available evidence.

Langue d'origineEnglish
Pages (de-à)e265-e309
JournalCurrent Oncology
Volume21
Numéro de publication2
DOI
Statut de publicationPublished - 2014

ASJC Scopus Subject Areas

  • Oncology

PubMed: MeSH publication types

  • Journal Article

Empreinte numérique

Plonger dans les sujets de recherche 'Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: A Canadian consensus'. Ensemble, ils forment une empreinte numérique unique.

Citer